New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

November 2022

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

 Nov 14, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Net Product Revenue Increased 13% and Prescriptions Dispensed Increased 17%, Over the Prior Quarter Prescription Refills Exceed 50% …

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

 Nov 09, 2022, 17:16 ET  CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 Read More »

Scroll to Top